Resistance to c-Kit inhibitors in melanoma: insights for future therapies

Area of Science:

• Oncology
• Molecular Biology
• Dermatology

Background:

• Activating mutations in the receptor tyrosine kinase c-Kit are prevalent in mucosal and acral melanomas.
• While c-Kit inhibitors are effective for gastrointestinal stromal tumors, their efficacy in c-Kit mutant melanoma is limited.
• Phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways are key downstream effectors of activated c-Kit.

Purpose of the Study:

• To investigate the role of PI3K and MAPK signaling in acquired resistance to c-Kit inhibitors in melanoma.
• To evaluate the potential of combination therapies targeting these downstream pathways for overcoming resistance.

Main Methods:

• Analysis of signaling pathways in melanoma cells with acquired resistance to c-Kit inhibitors.
• Assessment of cell proliferation and survival following concurrent inhibition of MAPK and PI3K signaling.

Main Results:

• Re-activation of PI3K and MAPK pathways was confirmed in resistant melanoma sublines.
• These resistant cells remained sensitive to combined inhibition of MAPK and PI3K signaling.
• Concurrent inhibition of MAPK and PI3K pathways demonstrated efficacy in overcoming c-Kit inhibitor resistance.

Conclusions:

• Durable responses in c-Kit mutant melanoma may necessitate combination therapies targeting critical downstream proliferative and survival pathways.
• The interplay between targeted therapies and anti-tumor immunity should be considered.
• Future combinatorial treatment strategies may benefit from incorporating immunotherapies.